C.R. Bard (BCR) 229.91 $BCR
LUTONIX(R) Global Real-World Registry 24-Month Outcomes Presented at VIVA 2016
BusinessWire - Thu Sep 22, 7:30AM CDT
C. R. Bard, Inc. (NYSE:BCR) announced the presentation of the final 24-month results from the LUTONIX(R) Global Real-World Registry at the Vascular Intervention Advances (VIVA) 2016 Meeting. These results are the first reported final 24-month outcomes for "real-word" registry data for Drug Coated Balloon PTA Catheters (DCBs). The registry includes a subgroup of patients with long femoropopliteal lesions (>140mm) treated with the LUTONIX(R) 035 DCB. A Premarket Approval Supplement for use in this subgroup population is currently under review with the U.S. Food and Drug Administration.
BCR: 229.91 (-1.44)
CR Bard (BCR) Gets FDA's IDE Approval for Lutonix DCB
Zacks Equity Research - Zacks Investment Research - Tue Sep 20, 7:49AM CDT
CR Bard Inc. (BCR) recently announced the receipt of an Investigational Device Exemption (IDE) approval from the U.S. FDA for its Lutonix 014 Drug Coated Balloon (DCB) to extend the primary endpoint of the product to a 6-month time frame.
HYH: 33.96 (-0.92), BCR: 229.91 (-1.44), QDEL: 22.71 (-0.08)
FDA Approves 6-Month Primary End Point for the Lutonix(R) Below-the-Knee Drug Coated Balloon
BusinessWire - Mon Sep 19, 4:37PM CDT
C. R. Bard, Inc. (NYSE: BCR) today announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) supplemental application to modify the primary endpoint to a 6-month time point for the Lutonix(R) 014 Drug Coated Balloon PTA Catheter (DCB). The Lutonix(R) 014 device is currently the only DCB in an IDE clinical trial in the U.S. for treatment of arteries below the knee (BTK).
BCR: 229.91 (-1.44)
Look for Shares of CR Bard to Potentially Pullback after Yesterday's 2.93% Rise
Comtex SmarTrend(R) - Thu Sep 15, 1:42PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $217.10 to a high of $223.50. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $217.36 on volume of 265,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BCR: 229.91 (-1.44)
CR Bard Rises 2.93% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Sep 15, 1:41PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $217.10 to a high of $223.50. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $217.36 on volume of 265,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BCR: 229.91 (-1.44)
Bard to Present at Morgan Stanley Global Healthcare Conference
BusinessWire - Tue Sep 06, 10:00AM CDT
C. R. Bard, Inc. (NYSE:BCR) today announced that it will present at the Morgan Stanley Global Healthcare Conference in New York City on September 13, 2016. Christopher S. Holland, senior vice president and chief financial officer, will discuss the Company in a presentation scheduled to begin at 1:30 PM Eastern Daylight Time.
BCR: 229.91 (-1.44), MS: 31.91 (-0.33)
CR Bard (BCR) Breaks Through Resistance at $221.54
Comtex SmarTrend(R) - Wed Aug 31, 8:51AM CDT
Shares of CR Bard (NYSE:BCR) have bullishly opened above the pivot of $220.86 today and have reached the first resistance level of $221.54. Investors may be interested in a cross of the next upside pivot targets of $221.97 and $223.08.
BCR: 229.91 (-1.44)
Watch for CR Bard to Potentially Pullback After Gaining 1.56% Yesterday
Comtex SmarTrend(R) - Mon Aug 29, 1:27PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $217.06 to a high of $220.60. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $218.13 on volume of 234,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BCR: 229.91 (-1.44)
SmarTrend Watching for Potential Pullback in Shares of CR Bard After 1.56% Gain
Comtex SmarTrend(R) - Mon Aug 29, 1:25PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $217.06 to a high of $220.60. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $218.13 on volume of 234,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BCR: 229.91 (-1.44)
After Yesterday's Decline of 1.10%, CR Bard Offers Investors Better Value
Comtex SmarTrend(R) - Tue Aug 16, 2:51PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $219.55 to a high of $221.56. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $220.86 on volume of 215,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BCR: 229.91 (-1.44)
Look for Shares of CR Bard to Potentially Rebound after Yesterday's 1.10% Sell Off
Comtex SmarTrend(R) - Tue Aug 16, 2:49PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $219.55 to a high of $221.56. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $220.86 on volume of 215,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BCR: 229.91 (-1.44)
CR Bard Falls 1.44% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Aug 03, 2:12PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $219.32 to a high of $222.63. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $220.45 on volume of 244,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BCR: 229.91 (-1.44)
SmarTrend Watching for Potential Rebound in Shares of CR Bard After 1.44% Loss
Comtex SmarTrend(R) - Wed Aug 03, 2:11PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $219.32 to a high of $222.63. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $220.45 on volume of 244,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BCR: 229.91 (-1.44)
Cardinal Health (CAH) Tops Q4 Earnings, '17 View Impressive
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 3:59PM CDT
Cardinal Health Inc. (CAH) reported fourth-quarter fiscal 2016 adjusted earnings of $1.14 per share, which beat the Zacks Consensus Estimate by a penny.
BCR: 229.91 (-1.44), ALGN: 94.13 (-1.54), CAH: 77.66 (+0.10), MMSI: 23.96 (-0.32)
CONMED (CNMD) Earnings & Sales Beat in Q2, '16 View Up
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:45AM CDT
CONMED Corporation (CNMD) reported second-quarter 2016 adjusted earnings of 47 cents per share, surpassing the Zacks Consensus Estimate.
ABC: 83.33 (-0.26), BCR: 229.91 (-1.44), ALGN: 94.13 (-1.54), CNMD: 39.83 (-0.21)
C.R. Bard (BCR) Beats Q2 Earnings & Sales, FY16 View Up
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 2:19PM CDT
C.R. Bard Inc. (BCR) reported adjusted earnings of $2.56 in the second quarter of 2016, exceeding the Zacks Consensus Estimate by a dime.
HYH: 33.96 (-0.92), BSX: 23.71 (-0.02), BCR: 229.91 (-1.44), ALGN: 94.13 (-1.54)
SmarTrend Watching for Potential Rebound in Shares of CR Bard After 4.07% Loss
Comtex SmarTrend(R) - Wed Jul 27, 2:05PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $221.01 to a high of $229.92. Yesterday, the shares fell 4.1%, which took the trading range below the 3-day low of $228.34 on volume of 467,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BCR: 229.91 (-1.44)
After Yesterday's Decline of 4.07%, CR Bard Offers Investors Better Value
Comtex SmarTrend(R) - Wed Jul 27, 2:03PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $221.01 to a high of $229.92. Yesterday, the shares fell 4.1%, which took the trading range below the 3-day low of $228.34 on volume of 467,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BCR: 229.91 (-1.44)
LabCorp (LH) Tops Q2 Earnings, View Up, to Buy Sequenom
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 12:16PM CDT
LabCorp (LH) reported a solid second quarter 2016 with adjusted earnings per share (EPS) of $2.31, up 10.5% from the year-ago quarter.
SQNM: 2.39 (-0.01), BCR: 229.91 (-1.44), LH: 137.39 (-0.44), COO: 180.97 (-3.53)
LabCorp Sees Balanced Growth; Covance Synergy on Track
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 6:00AM CDT
On Jun 20, 2016, we issued an updated research report on Laboratory Corporation of America Holdings (LH).
BCR: 229.91 (-1.44), LH: 137.39 (-0.44), HSIC: 164.45 (-2.83), COO: 180.97 (-3.53)
LUTONIX(R) Global Real-World Registry 24-Month Outcomes Presented at VIVA 2016
BusinessWire - Thu Sep 22, 7:30AM CDT
C. R. Bard, Inc. (NYSE:BCR) announced the presentation of the final 24-month results from the LUTONIX(R) Global Real-World Registry at the Vascular Intervention Advances (VIVA) 2016 Meeting. These results are the first reported final 24-month outcomes for "real-word" registry data for Drug Coated Balloon PTA Catheters (DCBs). The registry includes a subgroup of patients with long femoropopliteal lesions (>140mm) treated with the LUTONIX(R) 035 DCB. A Premarket Approval Supplement for use in this subgroup population is currently under review with the U.S. Food and Drug Administration.
BCR: 229.91 (-1.44)
CR Bard (BCR) Gets FDA's IDE Approval for Lutonix DCB
Zacks Equity Research - Zacks Investment Research - Tue Sep 20, 7:49AM CDT
CR Bard Inc. (BCR) recently announced the receipt of an Investigational Device Exemption (IDE) approval from the U.S. FDA for its Lutonix 014 Drug Coated Balloon (DCB) to extend the primary endpoint of the product to a 6-month time frame.
HYH: 33.96 (-0.92), BCR: 229.91 (-1.44), QDEL: 22.71 (-0.08)
FDA Approves 6-Month Primary End Point for the Lutonix(R) Below-the-Knee Drug Coated Balloon
BusinessWire - Mon Sep 19, 4:37PM CDT
C. R. Bard, Inc. (NYSE: BCR) today announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) supplemental application to modify the primary endpoint to a 6-month time point for the Lutonix(R) 014 Drug Coated Balloon PTA Catheter (DCB). The Lutonix(R) 014 device is currently the only DCB in an IDE clinical trial in the U.S. for treatment of arteries below the knee (BTK).
BCR: 229.91 (-1.44)
Look for Shares of CR Bard to Potentially Pullback after Yesterday's 2.93% Rise
Comtex SmarTrend(R) - Thu Sep 15, 1:42PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $217.10 to a high of $223.50. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $217.36 on volume of 265,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BCR: 229.91 (-1.44)
CR Bard Rises 2.93% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Sep 15, 1:41PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $217.10 to a high of $223.50. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $217.36 on volume of 265,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BCR: 229.91 (-1.44)
Bard to Present at Morgan Stanley Global Healthcare Conference
BusinessWire - Tue Sep 06, 10:00AM CDT
C. R. Bard, Inc. (NYSE:BCR) today announced that it will present at the Morgan Stanley Global Healthcare Conference in New York City on September 13, 2016. Christopher S. Holland, senior vice president and chief financial officer, will discuss the Company in a presentation scheduled to begin at 1:30 PM Eastern Daylight Time.
BCR: 229.91 (-1.44), MS: 31.91 (-0.33)
CR Bard (BCR) Breaks Through Resistance at $221.54
Comtex SmarTrend(R) - Wed Aug 31, 8:51AM CDT
Shares of CR Bard (NYSE:BCR) have bullishly opened above the pivot of $220.86 today and have reached the first resistance level of $221.54. Investors may be interested in a cross of the next upside pivot targets of $221.97 and $223.08.
BCR: 229.91 (-1.44)
Watch for CR Bard to Potentially Pullback After Gaining 1.56% Yesterday
Comtex SmarTrend(R) - Mon Aug 29, 1:27PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $217.06 to a high of $220.60. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $218.13 on volume of 234,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BCR: 229.91 (-1.44)
SmarTrend Watching for Potential Pullback in Shares of CR Bard After 1.56% Gain
Comtex SmarTrend(R) - Mon Aug 29, 1:25PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $217.06 to a high of $220.60. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $218.13 on volume of 234,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BCR: 229.91 (-1.44)
After Yesterday's Decline of 1.10%, CR Bard Offers Investors Better Value
Comtex SmarTrend(R) - Tue Aug 16, 2:51PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $219.55 to a high of $221.56. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $220.86 on volume of 215,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BCR: 229.91 (-1.44)
Look for Shares of CR Bard to Potentially Rebound after Yesterday's 1.10% Sell Off
Comtex SmarTrend(R) - Tue Aug 16, 2:49PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $219.55 to a high of $221.56. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $220.86 on volume of 215,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BCR: 229.91 (-1.44)
CR Bard Falls 1.44% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Aug 03, 2:12PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $219.32 to a high of $222.63. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $220.45 on volume of 244,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BCR: 229.91 (-1.44)
SmarTrend Watching for Potential Rebound in Shares of CR Bard After 1.44% Loss
Comtex SmarTrend(R) - Wed Aug 03, 2:11PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $219.32 to a high of $222.63. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $220.45 on volume of 244,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BCR: 229.91 (-1.44)
Cardinal Health (CAH) Tops Q4 Earnings, '17 View Impressive
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 3:59PM CDT
Cardinal Health Inc. (CAH) reported fourth-quarter fiscal 2016 adjusted earnings of $1.14 per share, which beat the Zacks Consensus Estimate by a penny.
BCR: 229.91 (-1.44), ALGN: 94.13 (-1.54), CAH: 77.66 (+0.10), MMSI: 23.96 (-0.32)
CONMED (CNMD) Earnings & Sales Beat in Q2, '16 View Up
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:45AM CDT
CONMED Corporation (CNMD) reported second-quarter 2016 adjusted earnings of 47 cents per share, surpassing the Zacks Consensus Estimate.
ABC: 83.33 (-0.26), BCR: 229.91 (-1.44), ALGN: 94.13 (-1.54), CNMD: 39.83 (-0.21)
C.R. Bard (BCR) Beats Q2 Earnings & Sales, FY16 View Up
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 2:19PM CDT
C.R. Bard Inc. (BCR) reported adjusted earnings of $2.56 in the second quarter of 2016, exceeding the Zacks Consensus Estimate by a dime.
HYH: 33.96 (-0.92), BSX: 23.71 (-0.02), BCR: 229.91 (-1.44), ALGN: 94.13 (-1.54)
SmarTrend Watching for Potential Rebound in Shares of CR Bard After 4.07% Loss
Comtex SmarTrend(R) - Wed Jul 27, 2:05PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $221.01 to a high of $229.92. Yesterday, the shares fell 4.1%, which took the trading range below the 3-day low of $228.34 on volume of 467,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BCR: 229.91 (-1.44)
After Yesterday's Decline of 4.07%, CR Bard Offers Investors Better Value
Comtex SmarTrend(R) - Wed Jul 27, 2:03PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $221.01 to a high of $229.92. Yesterday, the shares fell 4.1%, which took the trading range below the 3-day low of $228.34 on volume of 467,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BCR: 229.91 (-1.44)
LabCorp (LH) Tops Q2 Earnings, View Up, to Buy Sequenom
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 12:16PM CDT
LabCorp (LH) reported a solid second quarter 2016 with adjusted earnings per share (EPS) of $2.31, up 10.5% from the year-ago quarter.
SQNM: 2.39 (-0.01), BCR: 229.91 (-1.44), LH: 137.39 (-0.44), COO: 180.97 (-3.53)
LabCorp Sees Balanced Growth; Covance Synergy on Track
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 6:00AM CDT
On Jun 20, 2016, we issued an updated research report on Laboratory Corporation of America Holdings (LH).
BCR: 229.91 (-1.44), LH: 137.39 (-0.44), HSIC: 164.45 (-2.83), COO: 180.97 (-3.53)
